---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-26-000030"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2026-07-15T20:05:37+00:00"
generated_at: "2026-07-15T20:06:06.743648+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte director Heath Lukatch retires; John Markels appointed to board

## Summary
- Heath Lukatch retired from Vaxcyte board effective July 16, 2026; no disagreement with company.
- John Markels appointed as Class II director, term expiring at 2028 annual meeting.
- Markels will serve on Audit and Compensation committees; qualifies as independent under Nasdaq rules.
- Markels receives standard non-employee director compensation; annual equity grant currently $430,000.
- No transactions or arrangements between Markels and company requiring disclosure under Item 404(a).

## SEC filing metadata
- accession: 0001649094-26-000030
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2026-07-15T20:05:37+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/0001649094-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/pcvx-20260713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-26-000030
- JSON: https://secwatch.observer/filing/0001649094-26-000030.json
- Plain text: https://secwatch.observer/filing/0001649094-26-000030.txt

## Key facts
- Executive change
  Heath Lukatch retired as Director at Vaxcyte, Inc..
  - Action: retired
  - Role: Director
  source text: On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/0001649094-26-000030-index.htm
- Executive change
  John Markels was appointed as Director at Vaxcyte, Inc..
  - Action: appointed
  - Role: Director
  source text: Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/0001649094-26-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.